There is a form of deafness caused by genetic mutations, and until recently, there have been very limited, temporary solutions. The medical world has made great progress in treating deafness, including the development of cochlear implants. Now, there is a cutting-edge new development through gene therapy. There has been substantial research on genetic deafness, and further information on when and how this gene therapy will be universally available.
Even though hearing is something we may never think of while doing it, it is an extremely complicated function. There are approximately 150 genes that have been associated with your ability to hear, and researchers have been working to pinpoint the gene that has the largest effect on hearing. According to the National Institute of Health, “The auditory system must develop and function properly to enable normal hearing. Many genes are responsible for the formation of the auditory system. Any disruptions in structure or function can lead to hearing loss or deafness.”
Dysfunction in the OTOF gene has been shown to be the cause of this hereditary deafness, on which this gene therapy research has focused.
Gene therapy is the process of replacing a non-functioning or defective gene with a healthy, functioning version of the same gene. This is the process they are using to restore hearing associated with the OTOF gene. According to an article written by the Children’s Hospital of Philadelphia about this gene therapy, “Gene therapy for children with OTOF gene-related deafness seeks to restore hearing by injecting copies of normal OTOF genes into the inner ear. With normal OTOF genes, the sensory cells will be able to function so they can respond to sound and activate the auditory nerve to send impulses to the brain.” After having this procedure, some patients started to be able to hear for the first time after a few weeks, and then over the next few months, continued to improve.
There have been multiple clinical trials, and the results are exceptionally promising. One of the most notable trials was done by Zheng-Yi Chen, who is an associate scientist at Mass Eye and Ear in Boston. From an article by Rob Stein, a writer for NPR, “The approach appears to have worked for about 90% of the patients, who ranged in age from babies less than a year old to adults as old as 32, according to the new report.” Dr. Lawrance Lustig, who chairs the Department of Otolaryngology-Head & Neck Surgery at Columbia University’s medical school, comments, “Being able to restore natural hearing, I think, is a game changer for our field… I know of a lot of groups that are thinking about clinical trials for these more common forms of deafness.” Results from multiple clinical trials have been very similar across the board, providing a promising future in this treatment.
As of April 23, 2026, the U.S. Food and Drug Administration (FDA), has approved this treatment for children and adults across the nation. From the FDA website, “The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene.” FDA Commissioner Marty Makary, M.D., M.P.H. said, “Today’s approval is a significant milestone in the treatment of genetic hearing loss.” This approval is a significant step forward for the future of what this treatment could do, and researchers are still hard at work to make that future a reality.
This gene therapy treatment has changed many lives, and many more are to come. The medical world is continuing to evolve in some unbelievable ways; this treatment is only one incredible example of these advancements.
